SINGAPORE--(BUSINESS WIRE)--Alcon, Inc. (NYSE: ACL) released today the three-month interim results of the first controlled clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon’s space to reduce intraocular pressure in patients with open-angle glaucoma. The data were presented in a poster at the World Glaucoma Congress in Singapore.